First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus. Abstract #587

Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Aim(s): To compare the effect of octreotide (OCT), PAS and RAD on cell viability, proliferation, hormonal secretion and growth factors modulation, in primary cultures of human gastroenteropancreatic-NETs (GEP-NETs).
Materials and methods: We established 16 in vitro primary cultures of GEP-NETs, using PCR and immunocytochemistry to assess expression of SSTR and MTT and BrdU assays to assess cell viability and proliferation.
Conference:
Category: Basic
Presenting Author: MD Manuela Albertelli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#752 First In Vitro Study of Human Gastroenteropancreatic Neuroendocrine Tumors: Comparative Effect of Octreotide, Pasireotide and Everolimus
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Diego Ferone
#836 Grade Increases In Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor
Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETS/WHO) has proved reliable for prognostic stratification of gastroenteropancreatic tumors (GEP). Although anecdotes have been published, no single study has evaluated whether grade changes between primary site and metastases.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Prof Federica Grillo
#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures
Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: doctor Corinne Gerard
#584 KI-67 HETEROGENEITY IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS
Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETs/WHO) has proved reliable for prognostic stratification, however concerns exist on Ki67 heterogeneity.
Conference:
Category: Basic
Presenting Author: Dr Federica Grillo
#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture
Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Aura Dulcinea Herrera-Martínez
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.